Sema Sezgin Goksu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sema Sezgin Goksu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Fatih Ozbay
Department of Medical Oncology, Akdeniz University Faculty of Medicine, 07058 Antalya, Türkiye
2 shared publications - Mustafa Karaca
Department of Medical Oncology, Akdeniz University Faculty of Medicine, 07058 Antalya, Türkiye
2 shared publications - Sertac Vurgun
Department of Medical Oncology, Akdeniz University Faculty of Medicine, 07058 Antalya, Türkiye
2 shared publications - Ahmet Bilici
Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey
1 shared publication - Ali Murat Tatlı
Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
1 shared publication - Ayberk Bayramgil
Department of Internal Medicine, Istanbul Medipol University, Istanbul 34000, Turkey
1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 593
Baseline and Dynamic Clinical–Laboratory Risk Models for Early Progression or Death During PD-(L)1 Blockade in Advanced NSCLC: Development and Internal Validation
Background: We developed clinical–laboratory models for early progression or death within 90 days (EPD90) during PD-1/PD-L1 blockade in advanced non-small cell lung cancer. EPD90 is a pragmatic early-risk endpoint, not a diagnosis of hyperprogressive disease. Methods: This retrospective single-centre cohort included patients treated between January 2018 and March 2026. The four-item baseline score, EPS-4, combined bone metastasis, lactate dehydrogenase (LDH), albumin and C-reactive protein. Among patients alive and progression-free at day 42, D1 added six-week changes in neutrophil-to-lymphocyte ratio (NLR), and D2 additionally included LDH changes. Internal validation used bootstrap resampling and repeated cross-validation. Results: Among 282 patients, 83 (29.4%) had EPD90. In the common baseline complete-case set (n = 252; 76 events), EPS-4 had an apparent area under the curve (AUC) of 0.729 (95% confidence interval [CI] 0.665–0.793). In 238 landmark-eligible complete cases (56 subsequent events), adding NLR change increased AUC from 0.718 to 0.801. Adding LDH yielded an AUC of 0.816, a modest, statistically non-significant increment (delta AUC 0.016; p = 0.094). Bootstrap-corrected calibration slopes were 0.980 for D1 and 0.957 for D2. Conclusions: NLR provided the principal dynamic contribution. D1 is emphasized as the main dynamic model; D2 remains an exploratory extension with uncertain incremental value. Unavailable laboratory collection dates and lack of external validation limit interpretation. The models and proposed thresholds require independent validation before clinical use.
- 30 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 593
Open AccessBaseline and Dynamic Clinical–Laboratory Risk Models for Early Progression or Death During PD-(L)1 Blockade in Advanced NSCLC: Development and Internal Validation
Background: We developed clinical–laboratory models for early progression or death within 90 days (EPD90) during PD-1/PD-L1 blockade in advanced non-small cell lung cancer. EPD90 is a pragmatic early-risk endpoint, not a diagnosis of hyperprogressive disease. Methods: This retrospective single-centre cohort included patients treated between January 2018 and March 2026. The four-item baseline score, EPS-4, combined bone metastasis, lactate dehydrogenase (LDH), albumin and C-reactive protein. Among patients alive and progression-free at day 42, D1 added six-week changes in neutrophil-to-lymphocyte ratio (NLR), and D2 additionally included LDH changes. Internal validation used bootstrap resampling and repeated cross-validation. Results: Among 282 patients, 83 (29.4%) had EPD90. In the common baseline complete-case set (n = 252; 76 events), EPS-4 had an apparent area under the curve (AUC) of 0.729 (95% confidence interval [CI] 0.665–0.793). In 238 landmark-eligible complete cases (56 subsequent events), adding NLR change increased AUC from 0.718 to 0.801. Adding LDH yielded an AUC of 0.816, a modest, statistically non-significant increment (delta AUC 0.016; p = 0.094). Bootstrap-corrected calibration slopes were 0.980 for D1 and 0.957 for D2. Conclusions: NLR provided the principal dynamic contribution. D1 is emphasized as the main dynamic model; D2 remains an exploratory extension with uncertain incremental value. Unavailable laboratory collection dates and lack of external validation limit interpretation. The models and proposed thresholds require independent validation before clinical use.
- Open Access
- 24 August 2026
- Published by MDPI AG in Preprints.org
Baseline and Dynamic Clinical–Laboratory Risk Models for Early Progression or Death during PD-(L)1 Blockade in Advanced NSCLC: Development and Internal Validation
Background: Tumour-growth kinetics required to diagnose hyperprogressive disease are often unavailable in routine care. We developed baseline and dynamic clinical–laboratory models for progression or death within 90 days (EPD90), a pragmatic endpoint for early clinical deterioration, and assessed whether six-week laboratory change improved risk estimation. Methods: This retrospective single-centre cohort included consecutive adults with advanced or unresectable non-small cell lung cancer treated with PD-1/PD-L1 blockade between January 2018 and March 2026. EPS-4 combined bone metastasis, lactate dehydrogenase (LDH) >240 U/L, albumin < 3.5 g/dL and C-reactive protein >10 mg/L. Day-42 landmark models added log2 ratios of neutrophil-to-lymphocyte ratio (NLR) and LDH. Performance was assessed with 2000 bootstrap resamples and repeated cross-validation. Results: Among 282 assessable patients, 83 (29.4%) had EPD90. In common complete cases (n = 252; 76 events), EPS-4 had an AUC of 0.729 (95% CI 0.665–0.793). Among 238 patients alive and progression-free at day 42 (56 subsequent events), AUC increased from 0.718 for EPS-4 alone to 0.801 after adding NLR change and 0.816 after adding LDH change. The final increment from LDH was modest (ΔAUC 0.016; P = 0.094). Conclusions: Baseline EPS-4 and early NLR change identified higher-risk patients, but the models remain development-stage and require independent prospective validation.
- 24 August 2026
- Published by MDPI AG in Preprints.org
Open AccessBaseline and Dynamic Clinical–Laboratory Risk Models for Early Progression or Death during PD-(L)1 Blockade in Advanced NSCLC: Development and Internal Validation
Background: Tumour-growth kinetics required to diagnose hyperprogressive disease are often unavailable in routine care. We developed baseline and dynamic clinical–laboratory models for progression or death within 90 days (EPD90), a pragmatic endpoint for early clinical deterioration, and assessed whether six-week laboratory change improved risk estimation. Methods: This retrospective single-centre cohort included consecutive adults with advanced or unresectable non-small cell lung cancer treated with PD-1/PD-L1 blockade between January 2018 and March 2026. EPS-4 combined bone metastasis, lactate dehydrogenase (LDH) >240 U/L, albumin < 3.5 g/dL and C-reactive protein >10 mg/L. Day-42 landmark models added log2 ratios of neutrophil-to-lymphocyte ratio (NLR) and LDH. Performance was assessed with 2000 bootstrap resamples and repeated cross-validation. Results: Among 282 assessable patients, 83 (29.4%) had EPD90. In common complete cases (n = 252; 76 events), EPS-4 had an AUC of 0.729 (95% CI 0.665–0.793). Among 238 patients alive and progression-free at day 42 (56 subsequent events), AUC increased from 0.718 for EPS-4 alone to 0.801 after adding NLR change and 0.816 after adding LDH change. The final increment from LDH was modest (ΔAUC 0.016; P = 0.094). Conclusions: Baseline EPS-4 and early NLR change identified higher-risk patients, but the models remain development-stage and require independent prospective validation.
- Open Access
Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer
Background/Objectives: The study aimed to compare the treatment effectiveness of patients with locally advanced rectal cancer undergoing standard neoadjuvant therapy or total neoadjuvant therapy. It also sought to identify prognostic factors for disease-free survival and overall survival and parameters predictive of pathological complete response. Materials and Methods: A retrospective analysis was conducted on 239 patients diagnosed with locally advanced rectal cancer between 2016 and 2022 at several medical centers in Turkey. Clinical data, including neoadjuvant chemoradiotherapy types, chemotherapy regimens, surgical outcomes, and survival metrics, were collected. Statistical analyses included chi-square tests, Kaplan–Meier survival analysis, and Cox proportional hazard models to evaluate prognostic factors for disease-free survival and overall survival and logistic regression to identify predictors of pathological complete response. Results: Among 239 patients, 46.9% received total neoadjuvant therapy, while 53.1% underwent standard neoadjuvant therapy. Total neoadjuvant therapy was associated with a significantly higher pathological complete response rate (45.5% vs. 14.9% in standard neoadjuvant therapy; p < 0.001) and longer disease-free survival (median 124.2 vs. 72.4 months). The 3-year overall survival rate for all patients was 90.7%, and disease-free survival was 76.8%. Multivariate analysis identified pathological complete response (HR: 2.34), total neoadjuvant therapy (HR: 5.12), and type of surgery (HR: 8.12) as independent prognostic factors for disease-free survival, and pathological complete response and absence of lymphovascular invasion as independent prognostic factors for overall survival. Logistic regression analysis showed that total neoadjuvant therapy (OR: 4.40) and initial neoadjuvant chemotherapy (OR: 2.02) were independent predictors of achieving pathological complete response. Conclusions: Total neoadjuvant therapy significantly improves pathological complete response rates, disease-free survival, and overall survival in patients with locally advanced rectal cancer compared to standard neoadjuvant therapy. Total neoadjuvant therapy and achieving pathological complete response are strong independent prognostic factors for both disease-free survival and overall survival, suggesting that a more intensive neoadjuvant approach may lead to better outcomes in locally advanced rectal cancer. The increased pathological complete responses rate with total neoadjuvant therapy has created an opportunity for the development of new treatment modalities and the advancement of non-surgical management strategies in the future.
Open AccessComparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer
Background/Objectives: The study aimed to compare the treatment effectiveness of patients with locally advanced rectal cancer undergoing standard neoadjuvant therapy or total neoadjuvant therapy. It also sought to identify prognostic factors for disease-free survival and overall survival and parameters predictive of pathological complete response. Materials and Methods: A retrospective analysis was conducted on 239 patients diagnosed with locally advanced rectal cancer between 2016 and 2022 at several medical centers in Turkey. Clinical data, including neoadjuvant chemoradiotherapy types, chemotherapy regimens, surgical outcomes, and survival metrics, were collected. Statistical analyses included chi-square tests, Kaplan–Meier survival analysis, and Cox proportional hazard models to evaluate prognostic factors for disease-free survival and overall survival and logistic regression to identify predictors of pathological complete response. Results: Among 239 patients, 46.9% received total neoadjuvant therapy, while 53.1% underwent standard neoadjuvant therapy. Total neoadjuvant therapy was associated with a significantly higher pathological complete response rate (45.5% vs. 14.9% in standard neoadjuvant therapy; p < 0.001) and longer disease-free survival (median 124.2 vs. 72.4 months). The 3-year overall survival rate for all patients was 90.7%, and disease-free survival was 76.8%. Multivariate analysis identified pathological complete response (HR: 2.34), total neoadjuvant therapy (HR: 5.12), and type of surgery (HR: 8.12) as independent prognostic factors for disease-free survival, and pathological complete response and absence of lymphovascular invasion as independent prognostic factors for overall survival. Logistic regression analysis showed that total neoadjuvant therapy (OR: 4.40) and initial neoadjuvant chemotherapy (OR: 2.02) were independent predictors of achieving pathological complete response. Conclusions: Total neoadjuvant therapy significantly improves pathological complete response rates, disease-free survival, and overall survival in patients with locally advanced rectal cancer compared to standard neoadjuvant therapy. Total neoadjuvant therapy and achieving pathological complete response are strong independent prognostic factors for both disease-free survival and overall survival, suggesting that a more intensive neoadjuvant approach may lead to better outcomes in locally advanced rectal cancer. The increased pathological complete responses rate with total neoadjuvant therapy has created an opportunity for the development of new treatment modalities and the advancement of non-surgical management strategies in the future.
- Open Access
- 13 February 2021
- Published by Springer Nature in Cureus
- Vol. 13 (2)
Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery
Head and neck soft tissue sarcomas (HNSTSs) are a heterogeneous group of rare tumors. Surgical resection with negative margins remains the standard primary treatment for patients with HNSTS. The role of chemotherapy (CT) and radiotherapy (RT) remains controversial. In this multicenter study, we aimed to demonstrate the real-world assessing prognostic factors and the effect of adjuvant treatment modalities in adult patients with HNSTS treated with upfront surgery. We included a total of 47 patients who underwent curative-intent resection of a primary HNSTS between 2000 and 2019. The median follow-up was 29 months. The median age of patients was 51 years, and 66% of patients were male. The median relapse-free survival (RFS) of the study population was 31 months (range: 1.0-61.1 months), and the median overall survival (OS) was 115 months (range: 60.8-169.2 months). The univariable analysis revealed that treatment modalities showed a significant impact on RFS (p = 0.021); however, no difference was found in its impact on OS (p = 0.137). R0 resection did not showed impact on RFS (p = 0.130), but a significant association was found with OS (p = 0.004). In multivariable analysis, T stage of the tumor (hazard ratio [HR]: 3.834; 95% CI: 1.631-9.008; p = 0.002) and treatment with surgery and sequential RT and CT (HR: 0.115; 95% CI: 0.035-0.371; p < 0.001) were independent factors associated with RFS. R0 resection was independently associated with OS (HR: 4.902; 95% CI: 1.301-18.465; p = 0.019). Our study revealed that R0 resection improved OS, and T3-4 stage of tumor was a negative independent factor for RFS in surgically resected HNSTS patients. The use of sequential CT and RT after resection was associated with a better RFS, which emphasizes the importance of multidisciplinary evaluation of the treatment of HNSTS. Randomized prospective studies are needed
- 13 February 2021
- Published by Springer Nature in Cureus
- Vol. 13 (2)
Open AccessAssessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery
Head and neck soft tissue sarcomas (HNSTSs) are a heterogeneous group of rare tumors. Surgical resection with negative margins remains the standard primary treatment for patients with HNSTS. The role of chemotherapy (CT) and radiotherapy (RT) remains controversial. In this multicenter study, we aimed to demonstrate the real-world assessing prognostic factors and the effect of adjuvant treatment modalities in adult patients with HNSTS treated with upfront surgery. We included a total of 47 patients who underwent curative-intent resection of a primary HNSTS between 2000 and 2019. The median follow-up was 29 months. The median age of patients was 51 years, and 66% of patients were male. The median relapse-free survival (RFS) of the study population was 31 months (range: 1.0-61.1 months), and the median overall survival (OS) was 115 months (range: 60.8-169.2 months). The univariable analysis revealed that treatment modalities showed a significant impact on RFS (p = 0.021); however, no difference was found in its impact on OS (p = 0.137). R0 resection did not showed impact on RFS (p = 0.130), but a significant association was found with OS (p = 0.004). In multivariable analysis, T stage of the tumor (hazard ratio [HR]: 3.834; 95% CI: 1.631-9.008; p = 0.002) and treatment with surgery and sequential RT and CT (HR: 0.115; 95% CI: 0.035-0.371; p < 0.001) were independent factors associated with RFS. R0 resection was independently associated with OS (HR: 4.902; 95% CI: 1.301-18.465; p = 0.019). Our study revealed that R0 resection improved OS, and T3-4 stage of tumor was a negative independent factor for RFS in surgically resected HNSTS patients. The use of sequential CT and RT after resection was associated with a better RFS, which emphasizes the importance of multidisciplinary evaluation of the treatment of HNSTS. Randomized prospective studies are needed